Description | Upadacitinib(ABT-494)isaselectiveJAK1inhibitorwhichdemonstratesactivityagainstJAK1(0.045μM)andJAK2(0.109μM),with>40foldselectivityoverJAK3(2.1μM)and100foldselectivityoverTYK2(4.7μM)ascomparedtoJAK1. | ||||
---|---|---|---|---|---|
Targets |
| ||||
Invitro | UpadacitinibismostpotentonJAK1comparedtootherfamilymembers(JAK1 > JAK2 > JAK3 > TYK2).Upadacitinibdemonstratesselectivityacrossabroadpanelof70+kinases,withonlyRock1andRock2demonstratingIC50valuesbelow1μM.ConsistentwiththeBa/F3cellulardata,upadacitinibpotentlyinhibitstheJAK1dependentcytokinesIL-6,OSM,IL-2,andIFNγ,asmeasuredbyinhibitionofSTATphosphorylation[1]. | ||||
Invivo | Upadacitinibinhibitsdiseasepathologyinratadjuvantinducedarthritis[1].Itisanon-sensitivesubstrateforcytochromeP450,approximately20%iseliminated,unchanged,inurine[2]. |